Disease · MONDO_0005477
Targets27
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 27
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SCN5A | Sodium channel alpha subunit | 6 | Sodium channel alpha subunit blocker; Sodium channel protein type V alpha subunit blocker | Approval | https://conductscience.org/library/genes/6331 | Drugs and targets |
| ADRB1 | Adrenergic receptor beta | 5 | Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/153 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Approval | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN7A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6332 | Drugs and targets |
| SCN8A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6334 | Drugs and targets |
| SCN9A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6335 | Drugs and targets |
| ADRB2 | Adrenergic receptor beta | 3 | Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| KCNH2 | Voltage-gated inwardly rectifying potassium channel KCNH2 | 3 | HERG blocker | Approval | https://conductscience.org/library/genes/3757 | Drugs and targets |
| ADRB3 | Adrenergic receptor beta | 2 | Adrenergic receptor beta antagonist; Beta-3 adrenergic receptor agonist | Phase 2 | https://conductscience.org/library/genes/155 | Drugs and targets |
| CHRNA4 | Neuronal acetylcholine receptor; alpha4/beta2 | 2 | Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | Phase 2 | https://conductscience.org/library/genes/1137 | Drugs and targets |
| CHRNB2 | Neuronal acetylcholine receptor; alpha4/beta2 | 2 | Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | Phase 2 | https://conductscience.org/library/genes/1141 | Drugs and targets |
| ADRA1A | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/146 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 1 | Dopamine D2 receptor antagonist | Approval | https://conductscience.org/library/genes/1813 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005477/targets